IRVINE, Calif.–(BUSINESS WIRE)–Johnson & Johnson reports first real-world VARIPULSE Pro Platform data and 12-Month OMNYPULSE Platform outcomes for atrial fibrillation treatment
Tag: J and J
Recent
CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026
CorWave Completes Enrollment in Feasibility Study and Presents First Clinical Data on Adaptive Support with its Wave Membrane LVAD
Biograph Completes First U.S. Study with Caristo Diagnostics’ AI-Powered Coronary Inflammation Detection, Finding Risk in Over 42% of Asymptomatic Patients
Popular
- No commented posts yet